STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Peptide

MOTS-c

Also known as

Mitochondrial ORF of the Twelve S c · Mitochondrial open reading frame of the 12S rRNA-c · MOTS c · MOTSc · MOTS-C · mitochondrial-derived peptide MOTS-c · MRWQEMGYIFYPRKLR · MT-RNR1-encoded peptide

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Peptide Lots of talk Systemic SubQ Mitochondrial & metabolic peptides

Whole-body metabolic talk, with muscle as the organ people name.

What people say MOTS-c is an endogenous 16-amino-acid mitochondrial-derived peptide studied mainly in cells and animals. Gray-market native injections are not the same molecule or dose scale as the clinical analog CB4211. Doses people talk about
Repeated native weekly pattern5–10 mg/week SC

Total weekly amount appearing across forums and clinic-adjacent charts, commonly divided across one or two administrations.

Every-five-day pulse5 mg SC every 5 days

Older community charts describe four administrations across roughly 20 days followed by a long off-period; a separate author reported continuing 5 mg every five days in week four.

Daily community pattern0.5–2 mg/day SC

Reported daily or weekday use; weekly exposure varies with schedule, and direct comparisons with bolus patterns are absent.

These are uncontrolled gray-market practices, not validated clinical doses. They cannot be converted from CB4211 trial milligrams or animal mg/kg regimens.

Half-life & effect duration

Half-life in the body
  • Injected native MOTS-cNo settled estimate
Felt duration people report
  • Positive accountsStrong first effects or endurance changes
  • Other accountsNo noticeable effect, fatigue, sickness, headache or site soreness
  • Follow-upsRunning gains disappeared after stopping in one account; pronounced afternoon fatigue in another
Timing context & sources
How it may feel First-person reports conflict across the first doses and following weeks: striking energy or endurance, no clear effect, fatigue, sickness, headache, hunger and injection-site soreness all appear, often with other agents.
Cycles people discuss Older community notes describe four-dose, every-five-day pulses with long breaks and four-to-twelve-week blocks. A separate account describes 5 mg every five days through week four, not a completed pulse-and-break cycle. These are community schedules, not native-MOTS-c clinical protocols. Timing Morning or pre-training use is common; bedtime use also appears. Fasted versus fed timing has no established winner, and training or walking often accompanies positive reports. Stacks SS-31 is the most visible pairing, with conflicting sequence customs and concurrent use. NMN, GLP-1 drugs, humanin-family agents and exercise-mimetic compounds add further attribution problems. Watch for Injection site: Redness, itching, swelling, soreness, bruising or persistent areas appear in community reports; CB4211 development materials separately described formulation-related site reactions. Native MOTS-c and CB4211 are different molecules.
Related
SS-31HumaninNMNATX-304MTX-325

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

No dependable human elimination half-life for injected native MOTS-c was identified.

A small exercise study measured endogenous plasma and muscle abundance through four hours of recovery; that response cannot be converted into injected-drug pharmacokinetics.

Ten sedentary healthy young men, exercise stimulus rather than exogenous dosing, and no concentration-time elimination model.

Felt duration people report

Reports span acute strong effects, no noticeable effect, endurance changes, fatigue, sickness, headache and site soreness; no stable felt-duration range emerges.

One same-author update said running gains disappeared after stopping, while another reduced frequency after pronounced afternoon fatigue. Several reports used other peptides, GLP-1 drugs or hormone therapy.

Unverified products and amounts, uncontrolled exercise and diet, co-agent confounding, mixed authors and selective reporting; felt duration is not elimination half-life.

  • Rapamycin News — Does anyone try MOTS-c? (opens in a new tab)Posts 3–13: users discuss a five-week 10 mg/week cycle and SS-31/Humanin sequencing; one author reported faster running and later said the performance gain disappeared after stopping.Uncontrolled individual accounts, unverified products and mixed native-MOTS-c, analog and stack discussion.
  • r/PeptideGuide — MOTS-c experience (opens in a new tab)Original post and comments: amounts from 500 mcg to 20 mg per administration with varied schedules; reports include a strong first 5 mg exposure, later sickness/site soreness, endurance, fatigue, no effect and same-author updates.Different commenters, products, schedules and stacks; vendor-influenced subreddit; identity and amounts were not independently verified.
  • r/Peptidesource — Fatigue on MOTS-c (opens in a new tab)Original post and clarification: a 46-year-old woman described a week-four midday crash while using 5 mg every five days; SLU-PP-332, testosterone and an SSRI were also reported. Comments include no-benefit and varied fatigue experiences.Uncontrolled multi-agent reports, uncertain products and baseline fatigue; other commenters' accounts are separate observations.

Other context in this card

What people say 13

  • Fat loss / recomp: Forum and clinic-adjacent logs claim better body-comp or diet adherence while training; heavily confounded by diet, stacks, and GLP-1 adjacency. forum
  • Energy / work capacity: Users often describe steadier training energy and recovery over weeks rather than a stimulant “kick.” anecdote
  • Stack credit: Frequently praised inside multi-agent mito stacks (SS-31 + MOTS-c ± NAD axis ± humanin) where isolation is impossible. forum
  • Vs ATX-304 (2026): ATX logs get credited for “I loved ATX / go harder” after MOTS felt like a nothing-pin. That is comparison talk and cost/route talk, not a head-to-head RCT. forumanecdote
  • Insulin sensitivity: Preclinical work shows improved whole-body and muscle insulin action; HFD mice resist diet-induced insulin resistance with MOTS-c. animal
  • Obesity / weight models: Mice: blocks or blunts high-fat-diet weight gain; increases energy expenditure and fatty-acid oxidation talk in literature. animal
  • Aging metabolism / capacity: Late-life intermittent dosing in old mice (e.g. ~15 mg/kg 3×/week from ~23.5 mo) improved physical capacity and showed a modest median/max lifespan trend in one study — not a human lifespan claim. animal
  • Exercise-mimetic narrative: Endogenous MOTS-c rises with exercise (human muscle ~11.9× post-exercise; circulating ~1.5–1.6× then back to baseline by ~4 h). “Exercise in a vial” is community shorthand, not a proven substitute for training. trial
  • Heart / endothelium models: AMPK-linked protection and anti-inflammatory signaling (e.g. NF-κB-related talk) in animal cardiac/endothelial stress models. animal
  • Liver fat (analog only): CB4211 Phase 1b in obesity + NAFLD: ~25 mg SC daily × 28 days — ALT reduction and metabolic marker signals; not native MOTS-c data. trial
  • Bone (preclinical): Rodent work on osteoclast inhibition / bone parameters at mg/kg IP doses — research interest only, not a community primary use case. animal
  • Age biomarker story: Plasma MOTS-c often lower in obesity/T2D cohorts and with worse metabolic control; older adults may show different muscle vs plasma patterns. trial
  • Japanese longevity polymorphism talk: mtDNA m.1382A>C (Lys14Gln) discussed in longevity/haplogroup literature — complex, not a simple “MOTS-c boosts lifespan” human claim. trial

Doses people talk about 16

  • Dominant weekly band: ~5–10 mg total per week subcutaneous is the most repeated native protocol band across clinics, vendor charts, and forums. forum
  • Beginner / conservative: ~5 mg once weekly SC, or ~2.5 mg twice weekly (still ~5 mg/week total). forum
  • Standard split week: 5 mg SC 1–2× weekly, or ~2.5–5 mg Mon/Thu-style splits aiming at ~5–10 mg/week. forum
  • Higher community band: ~5 mg M/W/F (≈15 mg/week) or ~10 mg 2–3×/week appears in aggressive clinic/forum writeups; many users call 10 mg × 3/week “too high” relative to the common 5–10 mg/week total. forum
  • Classic “every 5 days × 20 days” protocol: Widely copied from peptides.org-style charts — 5 mg SC in the morning (often pre-exercise talk), every 5 days for 20 days (4 injections ≈ 20 mg total), then multi-month off before a possible second short course. forum
  • Daily / microdose camp: 0.5–1 mg SC daily (sometimes 1–2 mg/day or 1–1.5 mg weekdays) discussed as “steadier AMPK exposure”; total weekly can still land near 3.5–10+ mg depending on days used. forum
  • Daily vs bolus debate: Split community — bolus advocates say multi-mg shots “feel” more for energy/performance; microdose advocates prefer smaller daily pins and less site drama. No controlled head-to-head. forum
  • Per-injection ladder (vendor tables): Low ~5 mg / moderate ~7.5 mg / higher ~10 mg per injection appear on research-commerce charts — still usually capped by weekly totals in responsible writeups. forum
  • Load → maintain talk: Some charts describe titrating over ~4 weeks toward maintenance ~5–10 mg (frequency varies: weekly splits vs multi-day/week). forum
  • Timing: Morning and/or pre-training preferred in many protocols; empty-stomach talk is common but unproven as superior. Bedtime dosing appears in some clinic writeups. No controlled timing winner. forum
  • Reported routes: Subcutaneous administration dominates community accounts; intramuscular use appears less often. Injection-site redness, itching, soreness and persistent areas are reported, but technique guidance is outside this profile. forum
  • Purity / labeled-mg risk: Gray-market vials may not match label; third-party testing (e.g. Janoshik-style talk) is common community hygiene, not a guarantee. forum
  • Don’t copy ATX milligrams: ATX community talk is ~100–150 mg oral. MOTS community talk is ~5–10 mg/week SC. Not interchangeable. forum
  • CB4211 do-not-copy rule: Analog trial used ~25 mg SC daily × 4 weeks in Phase 1b NAFLD/obesity — orders of magnitude above typical native weekly totals; do not transplant CB4211 mg onto native MOTS-c. trial
  • Framing: All figures in this section are research/community discussion ranges only — not medical advice, not prescriptions, not validated clinical standards for native MOTS-c. forum
  • Animal units: Common rodent regimens include e.g. 15 mg/kg 3×/week (aging/capacity), 10 mg/kg IP (aging models), 2.5 mg/kg IP 2×/day short bursts — not 1:1 human schedules. animal

How it may feel 9

  • Injection day 0: Usually no stimulant rush; some report site sting/redness; minority describe rapid hunger or “blood sugar drop” shakiness (glucose-into-muscle narrative). anecdote
  • Days 1–7: Accounts conflict. One 5 mg twice-weekly author described a striking first exposure, a weaker second, then feeling sick with site soreness after later doses; others reported no clear effect, headache, heavy fatigue, or improved workouts. forum
  • Weeks 1–2: Some users reported stronger workouts or endurance; others described afternoon crashes, nausea, hunger or no effect. GLP-1 drugs, training, diet and multi-peptide stacks frequently confounded attribution. forum
  • Weeks 3–4: First real “is it working?” reassessment window for recomp or endurance logs; some clinic-adjacent reports of brain fog / flat mood around week 3–4 when training hard in a deficit (folate-cycle hangover lore — not proven). forum
  • Weeks 4–8: Body-comp, work-capacity, and “metabolic ease” anecdotes if calories/protein and progressive training are dialed. forum
  • Months 2–3: Longevity-style users may extend blocks; others prefer short pulses before cuts or camps. forum
  • After stopping: One runner later said a reported performance gain disappeared after discontinuation. This uncontrolled update is not a washout study or evidence of an elimination half-life. anecdote
  • No change by ~4 weeks: Community advice is usually recheck diet, sleep, training load, stack confounders, and purity — not automatic multi-fold dose jumps. forum
  • Vs the ATX swallow: MOTS is still “no stimulant kick, maybe site sting.” ATX is the daily capsule people contrast it with in 2026. forum

Around the dose 5

  • Clock: Morning or pre-cardio is the usual metabolic-mimetic slot. Night is less common. forum
  • Training: Often paired with the session — walk, zone-2, or lifting after the pin — because the story is “exercise-adjacent,” not a couch peptide. forum
  • Food: Some prefer fasted or away from a huge meal; not as locked as GH-axis empty-stomach lore. forum
  • Activity context: Training, walking and cardio commonly accompany positive accounts, so the peptide's contribution cannot be separated from the activity. forum
  • Vs ATX clock: MOTS is a pin timed to morning/training. ATX is a swallow. Don’t treat them as the same AM ritual. forum

Cycles people discuss 7

  • Short metabolic / recomp blocks: ~4–8 weeks on is common for body-comp and energy goals. forum
  • Longer performance / longevity-style blocks: ~8–12 weeks on appears often, then ~4–8 weeks off (or 2–4 weeks off in shorter-cycle writeups). forum
  • 20-day pulse: 4 × 5 mg every 5 days, then long off (sometimes framed as ~3–6 months or “repeat within six months”) — distinct from continuous multi-month weekly dosing. forum
  • 8 on / 4 off example: Clinic-adjacent tables often list ~8 weeks on, 4 weeks off with load ~10 mg/week then maintain ~5 mg/week. forum
  • Pattern preference: Community charts favor multi-shot weeks or structured every-5-day courses over sparse monthly “depot” pulses, often invoking a presumed short circulating half-life. That explanation does not establish a human elimination window or validate the schedule. forum
  • Re-runs: Often before cuts, camps, or hard training blocks; long-term continuous safety data for native gray-market use is lacking. forum
  • SS-31 sequencing cycles: Many stack writeups run SS-31 alone first (~2–4+ weeks “repair”), then add or switch toward MOTS-c; minority camp prefers MOTS-c first. Concurrent use also common. forum

Timing 8

  • Exogenous human PK: Formal gray-market native MOTS-c human PK is sparse. Community explanations assume short circulating duration to justify multi-weekly rather than monthly schedules; this is not a measured human timing rule. forum
  • Why multi-weekly (community rationale): Reports favor 1–3×/week boluses or daily microdoses rather than once-monthly dosing and explain that preference through presumed short blood presence. The schedule is a community pattern, not one established by measured human elimination. forum
  • Downstream claims: AMPK/mito signaling and training adaptations may last days–weeks after a pin in anecdotes; not a measured depot PK story. anecdote
  • Pre-workout timing experiments: Common practice; no controlled superiority vs non-training-day dosing. forum
  • Endogenous exercise response, not a half-life: In ten sedentary young men, plasma MOTS-c rose during and immediately after cycling and returned to baseline after four hours of rest. That time course does not establish injected MOTS-c elimination. trial
  • Muscle vs plasma: Muscle MOTS-c elevations after exercise can persist longer than the circulating spike; users sometimes interpret this as “downstream effects outlast blood levels.” trial
  • Delivery challenges (literature): Low bioavailability, poor stability, short half-lives, and tendency to linger at injection sites are cited as translation hurdles for MDP therapeutics. trial
  • BBB: Peripheral MOTS-c is generally described as not BBB-penetrant; CNS benefits in animals often required central or carrier-assisted routes. trial

More on what it is 7

  • Why people talk about it: Framed as an “exercise mimetic” and metabolic peptide for fat loss, insulin sensitivity, training energy, and longevity — endogenous levels rise with exercise and tend to fall with age/metabolic dysfunction. forum
  • Sport status: Discussed as a prohibited / experimental performance peptide in anti-doping context (USADA has warned athletes about research-labeled MOTS-c). forum
  • 2026 X comparison (not a rewrite): Nelly’s line — “ATX-304 is what everyone wanted MOTS-c to be” — is the 2026 heat: oral AMPK swallow vs MOTS as a short-lived pin. Same drawer, different bottle. forum
  • What it is: Endogenous 16-aa mitochondrial-derived peptide (sequence MRWQEMGYIFYPRKLR; ~2175 Da) encoded by a short ORF in mtDNA 12S rRNA (MT-RNR1). Translated in the cytosol with the standard genetic code. Research chemical / gray-market injectable; not FDA-approved as a drug. trial
  • Mechanism talk: Inhibits the folate–methionine cycle / de novo purine biosynthesis → AMPK activation; under stress can translocate to the nucleus (hydrophobic core 8YIFY11) and regulate nuclear genes; primary organ talk = skeletal muscle glucose uptake and metabolic flexibility. trial
  • Evidence honesty: Landmark preclinical work (Lee et al., Cell Metabolism 2015) plus extensive animal aging/exercise papers; large native-MOTS-c human outcome RCTs remain sparse. Human drug-development path largely via analog CB4211 (CohBar; Phase 1a/1b), not native peptide. trial
  • Not the same as: Not metformin, not a GLP-1 agonist, not SS-31/elamipretide (cardiolipin/ETC membrane repair), not humanin, and not CB4211 (different molecule and mg scale). trial

Stacks 13

  • Mito stack core: MOTS-c + SS-31 (elamipretide) — most discussed pairing. Bro lore: SS-31 = “hardware/repair” (cardiolipin/ETC); MOTS-c = “software/metabolic signal” (AMPK). No published combination RCT. forum
  • Sequence debate (SS-31 first majority): Common plan — SS-31 alone ~2–4+ weeks (often ~5–10 mg/day SC in community charts), then add MOTS-c or run both; rationale is prime/repair mito before metabolic push. forum
  • Sequence minority (MOTS-c first): Some influencers/clinics reverse order (metabolic signal first, then SS-31). Track which camp a protocol comes from. forum
  • Concurrent same-day: Some accounts overlap MOTS-c and SS-31 or place them on different training/recovery days. Simultaneous products and schedule changes prevent clean attribution of benefits or adverse effects. forum
  • Example concurrent ranges (discussion only): MOTS-c ~5–10 mg/week split + SS-31 daily community bands (SS-31 dose culture is its own rabbit hole — see SS-31 profile). forum
  • NAD axis: + NMN, NR, or injectable NAD+ in longevity circles; order talk sometimes “NAD first, then SS-31 + MOTS-c.” Confounded stacks. forum
  • MDP pairing: + humanin or analogs (e.g. HNG) as complementary mitochondrial-derived peptide interest — different pathways, shared “mito signal” branding. forum
  • GLP-1 adjacency: Sometimes layered with semaglutide / tirzepatide / retatrutide during fat-loss phases; watch hypoglycemia-like feel and appetite noise reports when combining metabolic agents. forum
  • SLU-PP-332 / exercise-mimetic stack: Low-dose MOTS-c + SLU-PP-332 + NAD talk appears in microdose logs (e.g. hundreds of mcg MOTS-c with SLU) — highly experimental, purity/confound heavy. anecdote
  • Training + diet as the real stack: Progressive training and calorie/protein control are repeatedly cited as required for recomp “results.” forum
  • Do not confuse with GLOW/KLOW/Wolverine blends: Those are BPC/TB/GHK/KPV healing blends — different category from MOTS-c mito signaling. forum
  • ATX pivot: 2026 stacks sometimes *replace* MOTS with ATX rather than running both AMPK stories. Glucose-stack caution if metformin/berberine is already there. forum
  • Metformin / AMPK caution lore: Shared AMPK-adjacent framing leads some to avoid stacking multiple AMPK activators blindly; ADDF notes possible interaction class with other AMPK-targeting drugs — not a mapped drug–drug trial. forum

Access talk 1

  • [object Object]

Storage notes 2

  • No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
  • Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Watch for 20

  • Injection site: Redness, itching, swelling, soreness, bruising or persistent areas appear in community reports; CB4211 development materials separately described formulation-related site reactions. Native MOTS-c and CB4211 are different molecules. trialforum
  • Early fatigue / heavy feel: Temporary first-week energy dip or muscle heaviness in some logs — ironic given energy goals. forum
  • Headache: Mild headache in first 1–3 doses (often ~2–6 h post-pin) is a recurring community cluster; usually fades with continued use per anecdotes. forum
  • Flushing: Occasional post-injection flushing reported. forum
  • GI: Minority nausea, stomach discomfort; one clinic page cites mild nausea ~10% — treat as local practice report, not RCT incidence. forum
  • Appetite / glucose feel: Sudden hunger, food noise, or shaky low-blood-sugar-like sensations after pinning (muscle glucose uptake lore); more notable if already on GLP-1s or under-eating. anecdote
  • Brain fog / flat mood (week 3–4 lore): Clinic-adjacent discussion links fog/mood flattening to heavy training + deficit around weeks 3–4 and folate-cycle mechanism talk — not established causality. forum
  • Cardio / sleep (rarer online reports): Palpitations, increased heart rate, insomnia — listed in USADA/self-experimenter summary material. forum
  • Fever (rare reports): Appears in anti-doping / online side-effect lists; sparse. forum
  • Histamine-like reactions: Itching → redness → hard swollen area lasting days reported at higher multi-mg EOD dosing; some drop to ~1 mg with rest days to tolerate. anecdote
  • Source quality: Contamination, underdosing, wrong peptide, or degraded product on research-chem market. forum
  • Analog / dose mix-up: Do not copy CB4211 25 mg daily schedules onto native MOTS-c 5–10 mg/week culture. forum
  • Pregnancy / medical conditions: Not characterized for special populations in community charts — clinical care required for any real-world medical decision. forum
  • Access / RUO: Gray-market vials remain the loud path. Compounded MOTS is not a settled pharmacy product as of this research date. forum
  • ATX mix-up: Buying ATX because “MOTS was supposed to be this” does not make MOTS oral, and does not make ATX a peptide. forum
  • Drug-class caution: AMPK-pathway overlap with other metabolic drugs is theoretical concern in reviews — no comprehensive interaction map for gray-market use. trial
  • Limited human native data: Safety of long-term native MOTS-c self-experimentation is not established; CB4211 short-term was “safe and well tolerated” with site-reaction caveats, and CohBar development discontinued. trial
  • Not risk-free / not approved: Research-only framing; not a substitute for exercise, nutrition, or medical care. Athletes: anti-doping risk. forum
  • 2026 compounding status: After 2023 Category 2 compounding restriction, writeups describe April 2026 Category 2 removal and a July 23, 2026 PCAC vote recommending MOTS-c for the 503A bulks list (close vote; FDA reviewers had recommended against). A committee vote is not a listing and not an approval. trial
  • WADA: Named AMPK activator (S4.4.1), prohibited in sport since the 2024 list — separate from compounding drama. trial

Updated: 2026-09-01

Evidence mix Mostly community / anecdote tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →